|1.||Mareš, Pavel: 1 article (06/2012)|
|2.||Rice, Kenner C: 1 article (10/2010)|
|3.||France, Charles P: 1 article (10/2010)|
|4.||Cheng, Kejun: 1 article (10/2010)|
|5.||Koek, Wouter: 1 article (10/2010)|
|6.||Froestl, Wolfgang: 1 article (01/2010)|
|7.||Ravnefjord, Anna: 1 article (02/2009)|
|8.||Lindström, Erik: 1 article (02/2009)|
|9.||Larsson, Håkan: 1 article (02/2009)|
|10.||Martinez, Vicente: 1 article (02/2009)|
02/01/2009 - "While CGP7930 was less efficacious than baclofen overall, positive allosteric modulation of GABA(B) receptors may represent a valid approach in the treatment of visceral pain conditions, with the possibility of an improved safety profile compared to full agonism."
02/01/2009 - "The GABA(B) receptor agonist, baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral pain-related responses to colorectal distension in rats."
06/01/2012 - "The 60-mg/kg dose of PTZ induced only mS in 4 out of 9 25-day-old rats; the 40-mg/kg dose of CGP7930 combined with this lower dose of PTZ resulted in the only proconvulsant effect--generalized tonic-clonic seizures appeared in two rats. "
06/01/2012 - "Minimal clonic seizures (mS) were moderately potentiated by low doses of CGP7930 in 18-day-old but suppressed by the highest dose in 25-day-old rats. "
06/01/2012 - "High doses of CGP7930 suppressed generalized tonic-clonic seizures in all five age groups. "
06/01/2012 - "Possible anticonvulsant action of CGP7930 was studied in a model of pentetrazol-induced seizures previously used for studies with agonists baclofen and SKF97541. "
|3.||Gastroesophageal Reflux (GERD)
01/01/2010 - "This chapter presents new clinical applications of the prototypic GABA(B) receptor agonist baclofen for the treatment of addiction by drugs of abuse, such as alcohol, cocaine, nicotine, morphine, and heroin, a novel baclofen prodrug Arbaclofen placarbil, the GABA(B) receptor agonist AZD3355 (Lesogabaran) currently in Phase 2 clinical trials for the treatment of gastroesophageal reflux disease, and four positive allosteric modulators of GABA(B) receptors (CGP7930, GS39783, NVP-BHF177, and BHFF), which have less propensity for the development of tolerance due to receptor desensitization than classical GABA(B) receptor agonists. "
04/01/2008 - "We therefore aimed to investigate the anxiolytic and side-effect profile of CGP7930, the first-reported GABA(B) receptor positive modulator, in rodent models of anxiety, motor coordination and hypothermia. "
10/01/2010 - "The results provide evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABA(B) receptors mediating loss of righting, but not at GABA(B) receptors mediating hypothermia. "
10/01/2010 - "In contrast with baclofen- and GHB-induced loss of righting, the hypothermic effects of baclofen and GHB were not enhanced by rac-BHFF but were enhanced by CGP7930 only at doses that produced hypothermia when given alone. "
04/01/2008 - "Similar to GS39783, CGP7930 also demonstrated a greatly reduced side-effect profile in comparison to the GABA(B) receptor full agonist baclofen in the mouse rotarod and traction wire tests and did not induce hypothermia. "
|2.||GABA-B Receptors (Receptor, GABA-B)
|3.||GABA-B Receptor Agonists
|4.||N,N'- dicyclopentyl- 2- methylsulfanyl- 5- nitro- pyrimidine- 4,6- diamine
|5.||Street Drugs (Illicit Drugs)
|7.||Morphine (MS Contin)
|9.||Cocaine (Cocaine HCl)